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Abstract
The hypothesis put forward in this paper is that we are currently observing a remarkable policy 
shift in the European Community concerning the conceptual basis and instruments for the 
governance of biopolitics. Biopolitics refers to an emerging policy field which involves the societal 
conflicts over the application of new genetic and reproductive technologies to humans 
(biomedicine) as well as the application of these new technologies particularly to agriculture and 
food production (biotechnology). The changes refer to the basic concept of how to govern the 
relationship between science and society, experts and lay-people, citizens and Eurocrats. The EC is 
opening up for incorporating ethical concerns into its research, technology and development policy 
as well as its regulatory biopolicies; furthermore, there is growing openness for “participatory” 
forms of biopolicy-making, yet the meaning of participation is limited. The reasons for this 
development are to be found in a more general trend in the transformation of European governance 
on the one hand aiming at involving civil society actors, and, on the other hand, in the 
characteristics of the policy field. These visions, spread out in the Commission’s White Paper on 
European Governance and several related policy papers, prove to be challenging for the Union as 
dynamic and multi-level polity. 
Kurzfassung
In diesem Beitrag wird die These vertreten, dass wir gegenwärtige eine bemerkenswerte 
Veränderungen im Hinblick auf die konzeptionelle und instrumentelle Ausgestaltung der Biopolitik 
in der EU beobachten können. Biopolitik bezeichnet ein neues Politikfeld, welches sowohl die 
Anwendung von genetischen und Fortpflanzungstechnologien am Menschen (Biomedizin) umfasst 
als auch die Anwendung dieser Technologien speziell in der Landwirtschaft und 
Lebensmittelproduktion (Biotechnologie). Die Veränderungen betreffen die Regulierung der 
Beziehung (governance) zwischen Wissenschaft und Gesellschaft, zwischen Experten und Laien, 
zwischen Bürgern und Eurokraten. Die EG öffnet sich für eine Inkorporierung von Ethik in ihre 
Forschungsförderpolitik und in ihre regulative Biopolitik sowie gegenüber neuen Modi von 
Governance in Gestalt von „partizipativen“ Verfahren, wobei hier ein verengter 
Partizipationsbegriff zugrunde gelegt wird. Die Gründe hierfür liegen zum einen in dem 
allgemeinen Trend einer Transformation von europäischen Governance-Strukturen und einer 
Beteiligung zivilgesellschaftlicher Akteure, zum anderen in den Charakteristika von Biopolitik. 
Diese Visionen der Europäischen Kommission, die sie sowohl im Weissbuch „Europäisches 
Regieren“ als auch in damit zusammenhängenden Dokumenten ausbreitet, sind eine 
Herausforderung für die EU als einem dynamischen Mehrebenensystem. 
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1 Introduction: Biopolitics in the European Union   
The question who should be involved in policy- and decision-making and what is the proper 
relationship between experts, lay-people and politicians is fundamental to democracies. Due to the 
strong tradition for deliberation and direct democracy in modern political theory and in public 
policy, there is a tendency to make policy- and decision-making more open to participation not only 
by stakeholders, but also by citizens. While this is essentially an old debate dating back to the Greek 
polis, it has been renewed with regard to advanced technologies in the last decades. Claims for 
involving a variety of social actors have been raised and the role of science particularly in regulatory 
policy-making has been widely discussed first in the US since the 1970s and for some years also in 
Europe. Biotechnology is an outstanding example, because of the alleged social impacts and, 
partially, unpredictable environmental and health risks which has even enforced the general 
participatory shift in technology assessment (TA) and policy-making. A variety of procedures has 
been conceptually and methodologically developed as well as practically tested that turn the focus 
from the traditional policy advice function of TA to the creation of a public sphere; the aim is to get 
citizens involved in discourses on science and technology.  
For some years biotechnology and biomedicine and their political regulation (biopolicies) have 
served as a hot issue in all member states of the European Union (EU) so that a dynamic biopolitical 
arena emerged.(1) For example, Eurobarometer 52.1 on “The Europeans and biotechnology”, the 
fourth survey in a series that cover biotechnology since the 1990s, shows that there is generally a 
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over time, even growing scepticism against “green” (agricultural) biotechnology in the late 1990s 
(cf. Durant et al., 1998; Gaskell/Bauer, 2001). Scepticism towards biomedicine and biotechnology 
focuses mainly not on the technology as such but on particular applications judged against the 
criteria of usefulness, supposed risks, and moral acceptability: While the vast majority is downright 
against genetically modified (GM) food, most people assess the detection of hereditary diseases as a 
good and morally acceptable purpose. However, some biomedical applications are regarded, in fact, 
as morally difficult, especially cloning and research on human embryos as well as the use of genetic 
diagnosis for preimplantation genetic diagnosis. The politicisation of green biotechnology does not 
mean that red biotechnology is immune to public opposition. On the contrary, the possibility of 
predictive medicine (e.g. genetic testing) has lately become an issue of public debate, for example, in 
Denmark, France, Germany and the Netherlands. Embryo and embryonic stem cell research are 
particularly contested matters in most member states and also at the supranational level in the 
context of the 6th Framework Programme for research, technology, and development (RTD). Not 
only the members states but also the European Community (EC) has to tackle these questions with 
regard to its RTD and its regulatory policy. Community competences in both areas have immensely 
increased. This is primarily an outcome of the common market as the central project of European 
integration. Public support for, in particular of advanced technologies, is thought to be vital for the 
competitiveness of European economy.  
The hypothesis that I want to put forward is that we are observing a remarkable shift particularly in 
the Commission’s position on how to govern biopolitics. “Participation” is the key word – yet 
reduced to a very limited concept, as I shall illustrate. The proposed “participatory” modes of 
governance aim at greater inclusiveness of social actors, i.e. experts and lay-people, stakeholders and 
citizens, the public and Eurocrats in supranational policy-making and regulation. The underlying 
assumption is that the effectiveness and efficiency, i.e. the output-side of policy-making, can be 
improved by strengthening the input-side and, in so doing, the legitimacy of EU policies will 
increase. This policy shift is particularly relevant in the area of biopolitics due to the ongoing 
political struggle especially over genetically modified (GM) food on the one hand and the assumed 
economic benefits on the other. Yet, it takes place within a fundamental discourse on European 
governance recently promoted, above all, by the European Commission which goes far beyond 
biopolitics and which has effects on the concept and limits of participation.  
2
Since any analysis of societal conflicts over new technologies has to take the very technological 
characteristics into account, I will first sketch the conflict dimensions involved (section 2). I will 
then illustrate the historical development of biopolicies in the EU starting with research policy and 
the development of European TA (section 3) before I turn to the development of regulatory policy-
making in this field (section 4). I will then introduce and analyse the relevant documents on 
governance and, in particular, on science and society published by the Commission over the last two 
years (section 5). In the final part, I will draw some conclusions for European governance (section 
6).  
2 Dimensions of biopolicies   
For a long time, EU policy-makers attributed the lack of acceptance of and resistance to biomedicine 
and biotechnology to people’s insufficient knowledge and irrational fears. A good example is the 
Bangemann report on the promotion of a competitive environment for biotechnology, it states:  
"At the same time, biotechnology suffers from a bad image amongst policy-makers and 
the general public … Although some of the expressed fears seem exaggerated they are, 
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public acceptability, and ethical questions raised, be recognised and dealt 
with." (Commission, 1991, p. 41)  
Policy measures focusing on better public relations and information campaigns are then judged to be 
major instruments for promoting social acceptability. This 'deficit model' blames the public for its 
ignorance as to the merits of science. However, Eurobarometer surveys illustrate that there is no 
linear relationship between knowledge and social acceptability: an increase in knowledge does not 
go hand in hand with an increase in acceptability.  
The public controversy over biomedicine and biotechnology (biopolitics) is strongly influenced by 
the very policy characteristics; three dimensions are deeply intermingled especially with regard to 
biomedicine, but also in biotechnology (cf. also Gill/Dreyer, 2001):  
Cognitive dimension: How can societies take decisions under the condition of intrinsic cognitive 
uncertainty, e.g., in relation to health risks associated with gene therapy or environmental hazards 
resulting from the deliberate release of genetically modified organisms (GMOs)? What does 
epistemological uncertainty and the knowledge about the inherent limits of scientific knowledge 
mean for the management of risks? There is a strong, ongoing trend towards a 'scientification of 
politics', i.e. the inflationary use of scientific expertise in public policy-making. Simultaneously, we 
observe the 'politicisation of science': the competition between expertise and counter-expertise 
reveals that science is not an objective and value-free endeavour, but a socially constructed sphere. 
Science has lost it authority, yet, policymakers still rely on it for advice (cf. Weingart, 1999). 
Furthermore, risk research, which is so prominent with respect to biotechnology and biomedicine, 
does have a cognitive bias. This holds also true for the precautionary principle which is regarded as a 
management instrument to deal with this epistemological problem. Yet, risk research and risk 
management both assume that the regulation of risks can be encountered by increasing knowledge; 
they underestimate the fact that the lack of knowledge is a basic component and requires new modes 
in the management of knowledge as well as a higher reflexivity of regulatory law and practices (cf. 
Bora, 2002).  
Interest dimension: Decisions over scientific and technological trajectories always involve conflicts 
of interest. For example, scientists are interested in doing research, medical doctors aim to help their 
patients, and industrialists want to sell new products and services; while patients’ groups want to 
benefit from new therapies and demand individual choices, activists of the disability movement fear 
genetic discrimination or compulsory use of biomedical applications once they are on the market. 
While environmental groups often want to ban genetically engineered food, industrialists want to use 
the new technologies in food processing but depend on a reliable regulatory frame that addresses 
standards and requirements. Policy-makers have to balance these opposing interests and have to keep 
the common good in mind. They must develop policies which satisfy social needs and do not lead to 
permanent social conflicts.  
3
Normative dimension: Risks deriving from technological inventions are perceived and judged 
differently according to social norms and cultural practices. In risk regulation 'objective' scientific 
values are “intertwined with more normative considerations. The acceptability of risk must therefore 
be weighed against normative values which are often strongly rooted in national traditions and 
cultures”. (Vos, 1999, p. 30) At the same time, dissent over fundamental normative issues could be a 
constant source of social conflict. Thus, how do liberal societies respond to such issues? What kind 
of procedures are suitable for solving the principal dilemma that “the 'law' cannot resolve the 
cognitive dimension of risks; 'science' cannot provide answer to the normative dimension” (Joerges, 
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have become a problem, for example, for social regulation of biotechnology and also with regard to 
embryo research in the fifth and particularly the sixth framework programme for RTD.(2)  
Governance practices have to take these different dimensions into account and to balance their 
influence in policy and decision-making. Cognitive approaches that focus solely on (scientific) 
knowledge and interests while ignoring the normative dimension are insufficient.  
3 Biopolitics and the development of European TA   
In this paper, I attend to a widespread definition of TA which includes, for example, technological 
foresight, parliamentary TA institutions, policy advice committees just as well as more deliberative 
practices. The core of TA is to combine scientific evaluations of (new) technologies with their social 
assessment. Policy-makers are a primary addressee of (formal) TA; a common goal is to inform them 
about technological and social options and, thereby, to improve policy-making. This policy advice 
function is central to the concept of TA from it inception in the late 1960s; however, since the 1990s 
TA is reorienting towards the public sphere (cf. Joss, 2002; Weale, 2001). Simon Joss and Helge 
Torgersen (2000, pp. 84f.) proclaim that  
" the European landscape of policy analysis and TA seems to have changed remarkably. 
While only a decade ago, there were just a small number of institutions actively 
pursuing participatory initiatives, nowadays there are dozens of organizations and 
individuals engaging in such activities. To be sure, there are still critical voices, and 
public participation is by no means fully established in institutional TA; but the issue 
has certainly moved more centre-stage." 
This turn to so-called participatory TA is, in fact, reflected on the supranational level. The brief 
historical reconstruction of this development and the predominant role biopolicies have played is the 
focus of this section of my paper.  
3.1 Development of European TA   
The founding of the Office of TA (OTA) at the US-Congress in 1972 was the starting point for a first 
wave in the institutionalisation of (parliamentary) TA in many West European countries and at the 
European level (cf. Vig/Paschen, 2000). The EC gained importance for the institutionalisation of TA 
in Europe by helping to build up relevant networks and by promoting the cooperation of 
organisations for TA founded in the member states (cf. Baron, 1995, p. 147). The programme 
“Forecasting and Assessment in Science and Technology” (FAST), set up in the mid-1970s, was a 
first attempt to build a community method for planning and forecasting of new technologies. One 
thematic focus of the FAST activities was the European 'biosociety'. The FAST group tried to 
formulate “A Community Strategy for European Biotechnology.” The effects of the FAST 
programme were rather limited because of the lack of strong ties with policy-makers, and of a firm 
institutionalisation within the community policies, especially RTD policy (Baron, 1995, 144; Weiler, 
1995, p. 149). Furthermore, the basic orientation of FAST, stressing societal demands, collided with 
a general enthusiasm for technology among conservative governments in the 1980s.  
4
For many years, the European Commission was the only institution attending to TA at the European 
level, even though the European Parliament become interested early on. In the mid-1970 when the 
parliamentary influence on European policies was still very limited, a proposal was made for a 
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the Commission; all attempts for a firm institutionalisation of TA were blocked (cf. Wennrich, 1999, 
p. 529). With the rise of counter-movements against nuclear energy and biotechnology in the 1980s 
and with the growing importance of RTD policy established in the Single European Act in 1986, the 
European Parliament took the initiative again. In 1987, a pilot project was set up for the 
establishment of a European parliamentary organisation for TA. In order to fulfil the responsibilities 
of the European Parliament on issues of socio-technical change and to defy the strong position of the 
Commission, the “Scientific and Technological Options Assessment Programme” (STOA) was 
finally set up.(3) STOA became an integral part of the Parliament’s administrative structure in 1992 
(Holdsworth, 2000). However, while the idea was to incorporate participation of the public and of 
stakeholders as well as to create a public sphere, STOA followed in fact a strong expertise and 
instrumental model of TA.  
The effect of STOA on the work of the European Parliament has been, at best, limited. The reasons 
are scarce financial and personnel resources, lack of continuity, the complicated institutional and 
cultural environment, unclear competences, an instrumental and science-driven focus, as well, as 
inadequate support by the Parliament itself (cf. Baron, 1995, 139ff.; Weiler, 1995, 163ff.; Wennrich, 
1999, pp. 532f.). Biotechnology and biomedicine have been areas of major concern for STOA, 
however with minor influence.(4)  
3.2 Biomedicine – a catalyst for the development of European TA   
From the very beginning of European TA with the FAST programme, biomedicine was important 
and centre-stage. In the 1980s, Parliament discussed the rapid development of biotechnology and 
biomedicine several times, either in response to policy proposals by the Commission or on its own 
initiative. Yet, it was the European Parliament and its objections to the Human Genome Analysis 
Programme, originally launched by the Commission under the provocative title “predictive 
medicine” in 1988, that has incited and challenged the development as well as the function of 
European TA (Abels, 2000). With support from some member states in the Council, Parliament 
seriously criticised the proposal for its title and its supposedly eugenic rationale. It demanded, among 
other things, the establishment of a programme for the study of the ethical, social and legal aspects 
of human genome analysis (ELSA) and a broad public debate. The concept of accompanying TA 
became important for approval of the Commission’s proposal in Parliament (and the Council). In the 
final programme proposal, ELSA became an essential part funded with one Mio. ECU for two years. 
ELSA’s main task was to win acceptance for the programme and to soothe the interinstitutional and 
public debate .  
This pragmatic ad hoc procedure and the installation of expertise-oriented TA have had long-term 
effects for the development of European TA. RTD policy, whose first rationale was to improve the 
competitiveness of European industry in a globalised economy, hitherto neglected normative and 
non-technical values. Conflicts in RTD policy were conflicts of interest, not of values. This changed 
dramatically starting with the Human Genome Analysis Programme. In the following RTD 
framework programmes, ELSA studies covered the whole field of biomedical ethics and of 
biotechnology. This means that around 1990, EC policymakers became receptive to the idea that 
technological innovations need to be “socially robust” to be successful. The presidents of the 
Commission, the Council and the Parliament decided that bioethics should become an integral part 
of RTD policy. Ethics and economy were no longer seen as opposing orientations, but as 
interdependent factors. Nevertheless in the beginning an instrumental conception of bioethics 
prevailed, as illustrated in the so-called Bangemann report on the competitive environment for 
biotechnology (cf. Commission, 1991, p. 41).  
5
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considered to be of utmost importance for the market success of biotechnology. Interestingly, some 
years later, the Commission interprets its policy shift as follows:  
" It may seem surprising at first sight that the Commission supported research on 
bioethics and even fundamental research on bioethics. But these new activities are in 
fact logically integrated into the larger scientific research programmes of the EC … 
Moreover, research on bioethics does indeed answer to a political need as bioethical 
considerations are playing a growing role in political debate within the European 
Union." (Biomedical & Health Research Newsletter Nr. 2/1995, p. 10; my emphasis)  
The Commission was in a central position to confront these barriers. In the 1990s, it concentrated on 
the following instruments:  
1. The outcome of the Presidents’ meeting in 1991 was a Commission communication on the 
integration of ELSA into all biotechnology and biomedicine related RTD activities. Bioethics 
and TA were integrated into the regular mechanisms of European RTD policy, and funding 
increased enormously.(5) Bioethical research is expected to fulfil two main tasks: Firstly to 
develop a set of guidelines for ethically responsible research funding; some research is 
excluded from the RTD programmes (e.g. germ line interference and human cloning), for 
some other provisions are set. Secondly, it should contribute to public debate and policy 
deliberation. Whether the studies are effective, and how to measure their success, is under 
debate. According to a STOA evaluation, it is quite unclear what role „the issue of public 
policy relevance plays in the Commission’s evaluation of the ethics research. In fact, it is not 
clear what role bioethics research plays in such evaluations at all“ (STOA, 1998, p. 50). STOA 
warns that the Commission perceives “ELSA, Biomedical ethics and public perception 
funding … as merely a public relations exercise or sop to the concerned” (ibid., p. 51).  
2. Along with the reorientation of RTD policy came some organisational restructuring in the 
Directorate-General for research. A special unit for ELSA was founded within the directorate 
for life sciences.  
3. The Commission has revised its structure for policy advice. In the course of the 1990s, it 
established several new groups for such purpose. The first such group was the Group of 
Advisers on the Ethical Implications of Biotechnology (GAEIB) set up in 1991; it consisted of 
first six, then nine members from law, philosophy, medicine, biology. Its task was to identify 
and define new ethical problems with regard to biotechnology, to assess these aspects and their 
potential influence on society and the individual, as well as advise the Commission. In 1998, 
GAEIB was suspended and the new European Group on Ethics in Science and New 
Technologies (EGE, 2001) set up. The groups consists largely of experts from the same 
scientific disciplines as GAEIB plus informatics; its mandate to assess all new technologies is 
confined by the competences as laid down in the treaties.(6) Yet again, the common-market 
approach to bioethics is evident:  
" On the basis of the principles laid down in the European Treaties (which make 
reference to the fundamental rights defined by the European Convention of Human 
Rights of the Council of Europe), the EGE endeavours to draw up common rules to 
enable the internal market to operate in accordance with Europe's ethical 
values." (EGE, 2001; my emphasis)  
A further high-ranking policy group, the Life Sciences High Level Group consisting of eleven 
biologists, was formed in April 2000 by Commissioner Philippe Busquin to inform the Commission 
on new developments in the so-called life sciences, and to generate proposals on how to further the 
dialogue between science and society.  
Seite 6 von 26 EIoP: Text 2002-019: Full Text
03.12.2002 http://eiop.or.at/eiop/texte/2002-019.htm6
3.3 Characteristics of supranational TA and policy-making   
Three conclusions can be drawn regarding the development at the supranational level from the 1970s 
to the late 1990s: Firstly, the European level relies on a instrumental and science-driven model of 
TA; generally, participatory structures have not been developed. The Commission sets up and makes 
use of scientific advisory committees; it utilizes its organizational resources and experiences to 
decide who gets access to European policy networks and who doesn’t. Policy- and decision-making 
on issues of science and technology is, above all, a “politics of expertise”. Epistemic communities, 
that is networks of professionals with recognized expertise and an authoritative claim to policy-
relevant knowledge, have easy and – above all – privileged access to European-level policymakers 
(cf. Haas, 1992; Zito, 2001). This has also become obvious in the EC comitology system dealing 
with these questions (see section 4). Yet, as the sociologist of science Sheila Jasanoff (1990) has 
forcefully argued: “The naïve vision of neutral advisory bodies 'speaking truth to power' should be 
renounced.” It is this focus on expertise in RTD regulatory and funding policy that has led to the 
accusation of technocratic governance suffering from a lack of public legitimacy (cf. Peterson, 
1995a; Radaelli, 1999; Zito, 2001).  
Secondly, we can observe the rise of bioethics. The responsiveness to and emphasis on bioethics in 
European TA is clearly rooted in the normative dimension of biopolitics – moreover, bioethics and 
TA are often thought of as the same. This development is not unique to the supranational level, but 
ethics has gained prominence in strategic decision-making and public policy in the member states as 
well (cf. Lindsey et al., 2001; Salter and Jones, 2002). In the 1970s and much of the 1980s, the 
predominant policy framing centred on risks; controversies were framed as scientific-technical 
debates. In the 1980s and, particularly, in the 1990s, we can see a fundamental change towards 
ethical framing of policies. Since 1997, ethics has taken centre stage in public, policy and media 
discourse. This is also obvious at the European level, if we look at the Council activities. Shortly 
after the cloning of “Dolly” the sheep, the Amsterdam Council accepted a resolution that prohibits 
the cloning of human beings. The Council requested that the Commission considers this aspect in the 
patenting directive, which was still under debate. The position against reproductive (as opposed to 
so-called therapeutic) cloning was confirmed in the “Charter of Fundamental Rights” first accepted 
at the Nice Council in December 2000, then acknowledged by the Commission and the European 
Parliament.(7) In addition, for the first time in EU history, the Stockholm Council in June 2001 
called attention to the need for a broad and open ethical debate on biotechnology as one of the most 
important technologies for Europe’s future; bioethics should become an integral part of the 
innovation process (Swedish Presidency, 2001). With regard to RTD policy, until the end of 2003 
the Council has to come up with shared ethical guidelines which regulate the funding of sensible 
fields such a embryo research. Finally, the outstanding position of ethics is also reflected in the 
changes introduced in the regulatory framework. For example, the new European Parliament and 
Council directive 2001/18/EC on the deliberate release of GMOs speaks of the possibility of 
introducing an ethical expertise into the regulatory procedure (see section 4). However, this turn 
towards bioethics poses new challenges for Community policy- and decision-making; current 
governance practices prove inadequate for these issues.  
Thirdly, since the days of Commissioner Edith Cresson, the Commission has tried to take the social 
prerequisites of technological innovations into account. John Peterson and Margaret Sharp point out: 
"The diffusion of innovations involves constant change and a reciprocal moulding 
process between technologies on the one hand and societies on the other. Yet, 
technology policy is a uniquely technocratic area of policy in which experts are 
powerful and the general public is not. Efforts by the Commission under Cresson to 
make EU-funded research more socially relevant and sensitive to the 'needs of society' 
reflect a new and general enthusiasm for open debates about how technology policy can 
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Including bioethics and integrating a wide range of scientific disciplines into the structures of policy 
advice was a way to tackle the growing sensitivity to social innovations. According to Christine 
Landfried (1997), these changes suggest a transformation of the Community “beyond technocratic 
governance”. However, it took some more years until a deeper policy shift began to mature.  
4 Regulatory biopolicies – between science and participation   
The historical changes outlined so far with regard to RTD policy influence the approach to 
regulatory issues. The development and dominance of regulatory policy has been widely discussed 
by scholars of European integration. Furthermore, the regulation of risks and the role of scientific 
expertise in decision-making, in particular with regard to food and technical standard-setting, has 
been a major topic (e.g. Joerges et al., 1997). Recently, outstanding institutional and policy changes 
have been introduced in EU risk regulation so that David Vogel (2001) speaks of a “new politics of 
risk regulation”. Biopolitics and above all the controversy over GM food has fostered these changes. 
Since the 1990s, the EC has become the most important actor for the regulation especially of 
biotechnology; it has developed a vertical and horizontal, process and product-related regulatory 
framework focussing on the special risks inherent in these new technologies. However, it is essential 
to distinguish the Community’s regulatory competences with regard to biopolicies. The EC Treaty 
assigns broad competences to the supranational level for biotechnology, while they are very limited 
in the area of biomedicine.(8) Health policy (of which biomedical policy is part) is still for the most 
part a national domain. Yet, some Treaty articles allow for measures related to biomedicine, 
especially in relation to research funding. So far, the main role has been to encourage biomedical 
RTD, which has become a controversial issue in the context of human genome research and, 
recently, embryo research. Yet, for one aspect the EC has strong regulatory power and that is 
pharmaceuticals. Since the early 1960s, the EC has harmonised the marketing authorisation for 
pharmaceuticals, and in 1995 two new procedures were introduced, one specifically for 
pharmaceuticals derived from genetic engineering (cf. Feick, 2002). While the new regulatory 
regime still allows for national authorisation procedures and subsequent mutual recognition, biotech 
(and all other innovative) pharmaceuticals have to go through a centralised procedure requiring 
approval by the European Agency for the Evaluation of Medicinal Products (EMEA) and leading to 
uniform and binding European decisions. Since drug development is a very long-term (and high-risk) 
process (it takes 10 to 15 years from the laboratory to clinical practice), and since the pharmaceutical 
sector has only started to invest in this development in the 1990s (this is partially an outcome of the 
Human Genome Project), more and more pharmaceutical will have to be authorised under this 
centralised procedure in the future.  
In biotechnology, distinctive and rigorous regulation has been developed since the 1990s pertaining 
to agriculture and food. The first two Community directives addressed the contained use of GMOs 
(Council Directive 90/219/EEC) and their deliberate release (Council Directive 90/220/EEC). The 
latter directive regulates experimental as well as market release of GMOs; it has become the 
cornerstone of Community regulation and was under massive critique from the very beginning (cf. 
Cantley, 1995; Gottweis, 1999; Patterson, 2000). Especially the market release of GM food and 
crops has led to massive conflicts at the supranational level, particularly via the comitology regime, 
that is, the complicated implementation procedure involving the competent national authorities and 
the Commission in the regulatory process. Christian Joerges and Jürgen Neyer (1997) claim that 
comitology committees are usually an efficient means of social regulation by “transforming strategic 
interaction into deliberative problem-solving”. Thereby, according to Joerges and Neyer, they 
Seite 8 von 26 EIoP: Text 2002-019: Full Text
03.12.2002 http://eiop.or.at/eiop/texte/2002-019.htmconstitute a special way of legitimising Community policies beyond the dichotomy of input versus 
output legitimacy. With regard to GMOs, however, rational deliberation and normative reasoning 
failed: In all cases where a competent authority approved the market release of a GMO, a competent 
authority in another member state raised objections and in so doing initiated the comitology 
procedure. “This was because the mutual recognition of risk assessment demanded by the directive 
did not occur since competent Authorities do not trust the risk-assessment carried out by other 
Competent Authorities”. (Toeller/Hofmann, 2000, p. 40) Material criteria for risk assessment and 
management, which are not fixed in the directive itself, were contested among the members of the 
Article-21 Committee in charge. The situation escalated with Ciba Geigy’s bt-maize in 1996: after 
having consulted several scientific committees supporting the Commission’s position pro market 
release, the Commission authorised the bt-maize against the outspoken will of 14 member states.(9) 
This incidence contributed, firstly, to an institutional reform of the comitology system itself (cf. 
ibid.), and, secondly, to a policy change: since 1999 there is a de facto moratorium for placing 
GMOs on the market.(10) The moratorium stressed the urgent need for a revision of the deliberate 
release directive which was finally adopted in early 2001 (EP/Council Directive 2001/18/EC). The 
new directive, coming into force in October 2002, attends to strong public concern and makes 
transparency as well as public participation in the national authorisation procedure compulsory.(11) 
Still, the new directive has not yet led to a lift of the ban on GMOs.  
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GM food has proved to be most controversial. Especially due to the BSE crisis and its mobilising 
effect on domestic publics, food safety has become the prominent policy frame. Vogel (2001, p. 13) 
states that “… mad-cow disease has shaped the way Europeans have framed the potentials risks 
associated with GMOs”.(12) The principle of mutual recognition applied also to GM food until the 
so-called novel food regulation (Regulation 258/97) was adopted in 1997 – again after years of 
intense debate (for a detailed reconstruction cf. Rückert, 2000). It introduced a harmonised, two-step 
procedure involving national food agencies and the Commission; accompanying regulations 
concerned, above all, labelling standards (cf. also European Commission, 2002b). Nevertheless, the 
regulation proved insufficient and some member states used the safety clause to ban the import of 
GM food. Finally, in 2000 the Commission proposed a new regulatory regime for food in its White 
Paper on Food Safety (European Commission, 2000e; cf. also European Commission, 2000d). At the 
heart of this new regime is the independent European Food Safety Authority (EFSA) formally 
adopted on 28th January, 2002. EFSA is of chief importance for the GMO debate, because it will 
provide scientific opinions on any issue related to GMOs (European Commission, 2001h, p. 2). The 
crucial aim is to win back public trust in the Community’s ability to effectively manage the risks 
posed to the environment and human health.  
In addition, the Commission proposed two new regulations in 2001 focussing on the traceability and 
labelling of food (ingredients) and feed that consist of, contain, or are derived from GMOs 
(European Commission, 2001f; European Commission, 2001g). It suggests establishing a 'one door –
one key' principle for the authorisation procedure of food and feed involving EFSA along with 
traceability and labelling of GMOs “from the farm to the fork”. As Commissioner David Byrne 
comments on the first reading in the European Parliament, the proposals “provide the right approach 
to foster public confidence and social acceptance of the application of biotechnology in agri-food 
production. They will also give legal certainty for business operators as well as facilitating trade”. 
(European Commission, 2002c)(13)  
The emerging food regime deserves some further consideration, particularly in comparison to other 
countries such as the US, where regulatory agencies have been introduced as a response to the 
regulatory crisis of the 1960s and 1970s. A characteristic feature of the EU food regime is that it 
distinguishes between risk assessment and risk communication, which is the duty of EFSA, and risk 
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counter-productive effects as, for example, Giandomenico Majone, Ed Randall, and David Vogel 
argue in their critique of the new regime.  
Majone is certainly one of the most important and outspoken advocates of regulatory policy and 
strong regulatory agencies in the EU (cf. Majone, 1996). In a recent article he has criticised the 
emerging European food safety regime. According to him, the EFSA structure reflects the changing 
meaning and the ambiguity of the precautionary principle. First introduced in the Maastricht Treaty 
in the chapter on environmental policy, the precautionary principle has been broadened to cover all 
human, animal and plant health. In its Communication on the precautionary principle (European 
Commission, 2000a), the Commission assigns it “the status of a 'central plank' of Community policy 
and, more ambitiously, the status of a general principle of international economic and environmental 
law” (Majone, 2002, p. 90). Majone claims that this principle has many theoretical as well as 
practical weaknesses, above all the lack of a clear definition besides the unclear effects on regulatory 
science, on integration and diversity as well as on free trade. He argues that the emphasis on the 
precautionary principle and the key status assigned to it “could be interpreted as a strategy to avoid 
or at least delay difficult institutional choices” (ibid., p. 107). He suggests establishing strong 
regulatory agencies with powers of rule-making and rule enforcement based on the US model of 
federal agencies.  
Majone reasons that the distinction between scientific risk assessment and political risk management 
leads to a politicisation of food safety which restricts the credibility of the new regulatory institution. 
This is, of course, of paramount importance in an already highly politicised policy area such as 
biotechnology and GMO where public opinion is highly divided and where some member states 
have an outspoken anti-biotech position due to the public controversy (resulting, for example, in an 
imposition of national bans on GMO products). This politicisation argument is supported by Ed 
Randall, who asserts that it brings about the real danger of secrecy and intergovernmental pork-
barrel politics.  
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"The real concern of those who believe that a sharp distinction between risk assessment 
and communication and risk management is unsound is a well founded fear that the 
squabbles and national rivalries and suspicions that have characterised EU decision 
making and risk management in the recent past will undermine the authority of both the 
EFA (European Food Authority; G.A.) and the Commissioner for Health and Consumer 
Protection in the future." (Randall, 2001).  
Yet, credibility of the new regime is an important issue. Vogel contributes an historical argument; he 
states that the current style in EC risk regulation resembles the risk-averse US approach during the 
1960s and through the mid 1980s. In the US, strong regulatory agencies helped to reconstitute 
citizen’s trust in the state’s capacity for successful risk management. Vogel implicitly assumes that 
this is a viable course for the Community as well, since the EC and US polity share important 
similarities such as a division of power in a multi-level system (Vogel, 2001, p. 18; cf. also Randall, 
2001).  
While these critical analyses certainly shed light on some most important aspects of the current 
debate, in my opinion, they do misjudge to some extent the nature of the problem and its institutional 
context. Firstly, the current regulatory crisis is not limited to the EU and its member states alone.(14)
The resistance to GMOs has influenced biopolitics far beyond the EU, for example with regard to 
world trade (cf. Skogstad, 2001), but also international food aid.(15) Martin Bauer and George 
Gasekell (2002) speak of “the making of a global controversy” which is, to some extent, induced by 
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observes, in fact, a “crisis of expertise” in the US just as in Europe. However, the political responses 
differ: The debate in the US focuses on the role of experts, on policies, and on specific issues such as 
biotechnology. The European debate, in contrast, is about the status of science in general, new forms 
of governance, institutional reform and the need for changing the relationship between science and 
society. Yet, participation is considered an adequate response in the EU as well as in the US.(16)  
The EU focus on governance and institutional change is linked to a second aspect: the state of its 
polity and fundamental differences to the US. The establishment of strong regulatory agencies in the 
US was, of course, a major and, according to Vogel, also successful institutional intervention. 
However, they were introduced into a historically grown political system with well established 
means for securing legitimacy, e.g. by introducing a system of notice and comment which allows for 
transparency and responsiveness of the regulatory system. These agencies work, in general, quite 
well in the field of biotechnology so that opinion polls show that the level of trust in the regulatory 
agencies is higher in the US than in the EU (cf. Gaskell et al., 2002). Yet, the conditions for choosing 
such institutional solutions are different in the EU: it is an evolving, dynamic and hotly disputed 
political system of intergovernmental and supranational character which poses new challenges for 
the problem of democratic legitimacy. It cannot rely as much on generalised public trust and support 
since it still has to develop ways to channel public opinion into supranational policy-making. The 
history of the biotech controversy shows that the existing institutions do have the capacity to channel 
public opinion, but it is limited and so far it has not been successful in terms of resolving the 
conflict.  
The limited capacity has to do, so I believe, with the nature of the conflict and its strong normative 
foundation. The argument that risk assessment and management are inseparable and should be in one 
hand, that is, the regulatory agency, is after all based on a cognitive and positivist premise that 
doesn’t sufficiently take the normative (and sometimes even ethical) dimension of technological 
conflicts into account. It underestimates the influence of norms in regulatory science and considers 
science-based knowledge as the only legitimate source of regulatory knowledge production and 
decision-making. However, a normative dimension is inherent in all social regulation, but it is of 
particular importance with regard to biopolicy. In her discussion of European agencies Ellen Vos 
points out that – at least in situations of scientific uncertainty – the “non-majoritarian governance 
model based on independent technocratic agencies clearly fails to recognise the value-laden nature of 
health and safety and environmental regulation” (Vos, 2000, p. 19; cf. also Neyer 2000; Joerges 
2001). Moreover, normative premises are often, indeed, part of the assessment procedure itself; 
therefore, there has to be a political debate. The dominant public view of the EU is already that of 
technocratic decision-making. Efforts to depoliticise a debate that is inherently political will not 
solve the basic problem.  
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This is also the official Commission’s position; it claims that the separation of risk assessment and 
management allows the necessary inclusion of other factors than science.  
"It is recognised that scientific risk assessment alone cannot, in some cases, provide all 
the information on which a risk-management decision should be based, and that other 
factors relevant to the matter under consideration should legitimately be taken into 
account including societal, economic, ethical and environmental factors and the 
feasibility of controls”. (European Commission, 2000d, p. 28) (17)  
The EFSA structure in my opinion tries to reflect some of these aspects by establishing a corporatist 
structure integration stakeholders and policy networks with national authorities, as well as by 
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transparent for the public (European Commission, 2000d, article 37); furthermore, it “shall develop 
appropriate contacts with consumer representatives and any other interested parties” (ibid., article 
41) and the management board shall include representatives of consumers and industry (ibid., article 
24). However, so far it practically not clear who should be involved in the production of regulatory 
knowledge, in which way and to what ends; the Commission’s statements are still very vague. This 
is not to say that there should not be regulatory bodies, there is of course an urgent need. The 
normative and the science-based assessment are complementary; the normative assessment does 
require a science input. Yet, both modes of assessment of technological risks do operate under the 
Damocles sword of uncertainty and the intrinsic lack of knowledge (cf. Bora, 2002). Whether or not 
the EFSA will be efficient in solving or channelling the biopolitical debate is still an open question. 
If it is to be successful, it is important to consider how it fits into the overall governance design and 
the ongoing “participatory” shift in the EU.  
5 Contextualising the “participatory” shift: Reforming 
European governance   
The reform of European governance has held top priority on the agenda since early 2000. The 
current crisis to which the Community is attempting to respond is not limited to risk regulation only, 
but is essentially part of the deep “democratic deficit” of the EU and its legitimacy crisis. This is the 
reason for the prominent place of risk regulation and biopolitics in the White Paper on Governance 
and related policy papers the Commission has published in the last two years. One of the most 
striking features these policy papers share is their “participatory” speech: They emphasise the need 
for input legitimacy and take this as a means for strengthening output legitimacy. They are all 
concerned with new institutional and procedural mechanisms for more “participation” by creating a 
public sphere and including stakeholders, the general public and citizens in Community policy-
making. Science and technology – in particular, biotechnology – assume a prominent place; it is in 
this context that the Commission speaks of the need for a “new societal contract”. While this focus 
on participation is itself very remarkable, a closer analysis of what participation means in this 
context and how it is operationalised reveals that the Commission basically applies a very limited 
concept that can be characterised as “participation via consultation” rather than participation as used 
in theories of, for example, participatory democracy.  
5.1 Challenges and principles of European governance: the White Paper   
The long awaited White Paper on European Governance (European Commission, 2001a) addressed 
to the Member States, public authorities, and civil society provides the most general outline of the 
Commission’s view of the problem.(19) For the Commission, the starting point is that “people 
increasingly distrust institutions and politics”; this is “particularly acute at the level of the European 
Union” (ibid., p. 3). The goal of the White Paper is “to open up policy-making to make it more 
inclusive and accountable. A better use of powers should connect the EU more closely to its citizens 
and lead to more effective policies.” (Ibid., p. 8) For the Commission there is a very strong link 
between input and output legitimacy. Key principles of “good governance” referring to input 
legitimacy are openness, participation, and accountability. In the Commission’s vision, consultation 
of and dialogue with civil society, that is a wide range of interest groups, associations and grass-roots 
organisations, enjoys a prominent role, because “civil society plays an important role in giving voice 
to the concerns of citizens and delivering services that meet people’s needs” (ibid., p. 14).  
11
At first sight, it seems striking that the Commission is adopting such an input approach. Scholars of 
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necessary systemic prerequisites for input legitimacy; according to Scharpf, the EU can only rely on 
output legitimacy. The options laid out in the White Paper raise the question as to why the 
Commission is advocating a participatory governance model. In the past, the Commission has 
proved a very successful architect of policy networks. These networks allow the formal and informal 
interaction of public and private actors from a heterogeneous background. The networks are 
sometimes very open, inclusive and bottom-up but often very elitist, exclusive, and top-down 
(Kassim, 1994; Peterson, 1995b). Experts, i.e., scientific experts as well as representatives of interest 
groups(20), do take a central position in these policy networks, because the Commission depends 
heavily on external expertise. The remarkable committee system is the main route via which 
expertise is integrated (cf. Pedler and Schaefer, 1996; van Schendelen, 1998; Christiansen/Kirchner, 
2000).  
Bearing this in mind, the Commission’s commitment to a participatory approach is less amazing, 
since it puts the Commission in a central position as a policy-broker. In this sense, the 
interinstitutional battle for policy-making power as well as shifting weights in favour of the 
European Parliament (due to the co-decision procedure) are the background for the Commission’s 
vision of European governance (cf. Héritier, 2001; Laffan, 2002; Wincott 2001). The Commision 
attempts to gain back lost ground by promoting a concept that puts itself in a key position.  
In the White Paper, the Commission considers the relation between science and society a crucial area 
for European governance (cf. European Commission, 2001b), explicitly mentioning biotechnology. 
Policy-making and regulation rely very much on expert advice, but biotechnology has illustrated that 
advice beyond 'pure' science is necessary, and that there is need for public confidence in expert-
based policy-making (cf. ibid., p. 19). The Commission suggests a multi-disciplinary expert system 
and the creation of a European scientific reference system to support community policy-making, in 
order to democratise expertise. In so doing, it can handle the “challenges, risks and ethical questions 
thrown up by science and technology” (ibid., p. 33). In the final analysis, a lack of public confidence 
is the fundamental problem for the Commission. Hence, the task of the Community institutions, 
above all the Commission, and of experts is to rebuild this confidence by integrating the citizenry. 
The next question is: How is this 'trust model' further elaborated in the sectoral policy papers on 
science and society?  
5.2 Science and society – sectoral visions for European governance   
In addition to the White Paper, the Commission has published several sectoral papers, for instance 
the Communication on the European Research Area (ERA) that address general questions of 
governance in RTD policy. It has furthermore published papers on the relation between science and 
society. Les Levidow and Claire Marris (2001, p. 348) claim that these papers indicate a change in 
the Commission’s own view of the science/society relation “from public ignorance to loss of trust”. 
So far, the Commission has attributed societal opposition and resistance to biotechnology to a lack of 
public understanding, to people’s fear and ignorance (cf. Commission, 1991), now trust is the new 
catchword. This 'trust model' already mentioned in the White Paper requires a new tools: better 
communication between researchers, industry, policymakers and citizens – and participation.  
In the ERA papers (European Commission, 2000b; European Commission, 2000c), the Commission 
starts with a negative diagnosis of the current situation for research in Europe. The Community is at 
risk of losing the race for growth and competitiveness in a global economy, “Europe might not 
successfully achieve the transition to a knowledge-based economy” (European Commission, 2000b, 
p. 4). Science and technology, and particularly biotechnology, are vital for such transition. However, 
the public image of science is “less positive than it was. Scientific progress seems to inspire as much 
anguish as hope ” (ibid., p. 5). It is this context, when the Commission suggests new modes for 
governing RTD, particularly a harmonisation of (so far) complementary and often competing 
research policies between member states and the Union. I do not want to address the problems this 
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Commission perceives the relationship between science and society. In the ERA Communication, the 
Commission attends to this problem in the final (!) chapter, “An area of shared values”. It 
recommends developing “new and sustained forms of dialogue between researchers and other social 
operators” (ibid., p. 20). The Commission refers to consensus conferences, an instrument of TA 
known for its radical participatory approach, “organised at European level on issues emerging at that 
level” as a means for “ordinary citizens” to express their opinions and concern on issues of science 
and technology (ibid.) – “at least experimentally” (European Commission, 2000f, p. 16).(21) 
Furthermore, the ethical dimension “especially in fields such as life sciences” regarding issues such 
as cloning or embryonic tissue could be strengthened by establishing closer links between ethics 
committees set up at the national and European levels (European Commission, 2000b, pp. 20f.).  
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In the policy paper on science and society as well as in the action plan, the Commission further 
elaborates this concept (European Commission, 2000f; European Commission, 2001d). It repeatedly 
confirms the need for a “new partnership” (European Commission, 2001d, p. 4) by promoting open 
dialogue between researchers, industrialists, policymakers, interest groups and the public (European 
Commission, 2000f, pp. 6, 16) especially at the European level, but also at the national, regional and 
local levels (European Commission, 2001d, pp. 12f.). The Commission denounces a simplistic and 
linear model of technological innovation from scientific invention to useful application; 
technological innovations are recognised as outcomes of social networks that incorporate a wide 
range of social actors, including users (ibid., p. 8). People should be involved, “particularly in 
defining the priorities of publicly-funded research” via consultative and advisory bodies (ibid., pp. 
8f.) in order to “bring science policy closer to the citizens” (European Commission, 2001d, pp. 5, 
14). The experiences with participatory research policy-making – a supplement to formal decision-
making –, “now need to be widened and deepened to systematically include other sectors of civil 
society at all stages” (ibid., p. 14).  
Levidow and Marris welcome the Commission’s initiative, but they are most critical about the way 
the science/society issue is dealt with. According to them, this new rhetoric of openness is double-
edged and contradictory, because participatory talk often just covers the former 'deficit model':  
"the new focus on a crisis of 'confidence' has not entirely abandoned preconceptions 
about misplaced fears or public ignorance. … On the one hand, official proposals for 
'stakeholder dialogue' are put forward as a novel approach, developed from lessons 
learnt from past paternalistic institutional behaviour. On the other hand, they continue to 
frame the problem as a gap between scientific knowledge and public anxiety – 
presumably a gap between rational judgements and irrational concerns. 'Public debate' 
and 'input from society' are sought mainly as a means to restore the legitimacy of 
science and technology, not as a means to reconsider innovation 
processes." (Levidow/Carr, 2001, p. 348)  
They continue that 
“thus, in these official discourses, public distrust is often still attributed to deficient 
public knowledge of science. Consequently, better communication is still seen as a key 
solution” (ibid.).  
While ethical concerns are now taken into consideration, they are believed to be “extra-scientific”. 
Scientific and other arguments are characterised as separable. While the first are still perceived to be 
objective, the last one is attributed to the subjective realm and are, therefore, of secondary 
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expert advice is too often simply equated with science. In so doing, the public is still the source of 
the problem; but in accordance with Levidow and Marris, this is a fundamental misdiagnosis.(22) 
The authors conclude that the perception of science and technology as “objective basis for 
policy” (ibid., pp. 356f.), in fact, does create the legitimacy crisis. Yet, if the aim is to relegitimise 
decision-making, government will need to 'un-learn' many institutional assumptions and to redefine 
the problem at stake. Rather than seeking ways to change the public, it is necessary to change the 
institutions responsible for promoting innovation and regulating risks. (ibid., pp. 357f.)  
To them, wider participation of lay-people should not be restricted to the assessment of innovations 
once there are near to the market, but to trajectories in research policy in general.  
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5.3 Visions for the governance of biopolitics   
I presume that biopolitics puts models for European governance in the field of science and 
technology to the test. As declared by the Commission, “GMOs, and more specifically transgenic 
plants, have come to symbolise all that is wrong in the relationship between science and 
society” (European Commission, 2001e). In order to “break the deadlock” (ibid.), it has recently 
published a document “Life sciences and biotechnology – A strategy for Europe” (European 
Commission, 2002a). The Strategy Paper is the outcome of a consultation process the Commission 
initiated with its Consultation Document “Towards a strategic vision of life sciences and 
biotechnology” (European Commission, 2001c). This document is an expression of the new 
governance strategy. The Commission invited “comments from citizens, consumers, as well as 
organised civil society, scientists, public authorities and operators with economic interests in 
industry, agriculture of services to contribute to the Commission’s reflections” (ibid., p. 5). In the 
Consultation Document, the Commission outlines basic problems and questions on a range of issues 
related to biotechnology, from ethical implication, to regulation, public involvement to trade, 
international collaboration and development policy.  
The document starts from the assumption that the life sciences have a vast potential for ensuring the 
competitiveness of European industry (ibid., p. 3f.). The challenge is to transform research into new 
products and services; the successful transformation requires a society fully committed to 
technological innovation.  
Most importantly, this potential can only be realised if there is broad public support. Consequently, 
there is increasingly a need for awareness and enlightened policy decisions on the societal priorities, 
and in particular on the societal framework and the ethical basis for development and applications of 
the new sciences and technologies. (Ibid., p. 4)  
Ethics as well as social or economic implications biotechnology are perceived to be of “key 
importance” for public perception and, therefore, they have to be properly dealt with. “The key to 
success lies with all stakeholders in Europe – public authorities, science, economic operators and 
consumers as well as the general public.” (Ibid.) In short, the issue of science and society is thought 
to have a direct effect on Europe’s economic future. The Commission concludes that the life sciences 
are of “strategic importance for Europe’s quest to become a leading knowledge-based economy” – 
an opportunity Europe “cannot afford to miss” (ibid., p. 27). The broad public debate has 
demonstrated the challenge to find “socially acceptable solutions”. Therefore, the “key to resolve the 
apparent dilemmas lies with Europe’s citizens”, and that is why the Commission invites comments to 
its policy proposal.  
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deterministic vision for biopolitics: the choices for Europe are “either a passive and re-active role, 
and bear the implications of the development of these technologies elsewhere, or develop pro-active 
policies” (European Commission, 2002a, p. 3). The Commission holds “uncertainty about societal 
acceptance” responsible for the lack of attention to biotechnology in Europe, which, in turn, has had 
negative effects on economic performance. The basis question is: “How can Europe deliver 
effective, credible and responsible policies which enjoy the confidence and support of its 
citizens?” (ibid., p. 5; my emphasis). Ethical and societal implications are important to consider. Yet, 
the choice for the Community is “not whether, but how to deal with the challenges posed” (ibid., p. 
3).  
Chapter 4 of the Strategy Paper deals with the science/society issue; here the Commission refers to 
its Action Plan discussed above (European Commission, 2001d). Governance of biotechnology, that 
is “the way public authorities prepare, decide, implement and explain policies and actions” (ibid., p. 
11), is called a “key element for responsible policy”. For the Community, five lines of action are 
important: societal dialogue, a development “in harmony with ethical values and societal good”, 
demand-driven applications, public confidence through science-based regulation, and respect for 
Community and international regulatory principles and legal obligations. The Commission stresses 
the need for “constructive” and “meaningful” dialogue open to all stakeholders, which has to be 
“balanced and rational” (ibid., p. 12). It distinguishes between “real issues” and “false claims”, 
without explaining how to draw this distinction. Who is to decide which is which? The key 
significance of the dialogue is “to help the public and stakeholders better understand and 
appreciate” (ibid., p. 13) the complex issues raised by biomedicine and biotechnology. Yet, the 
Community should actively pursue this dialogue; it should be on-going, and not restricted to product 
regulation only. In the action plan annexed, the Commission announces its intention to take the 
initiative for establishing a “broadly based Stakeholders’ Forum” and for encouraging public debates 
(Action 13). The Commission wants to strengthen research into socio-economic and ethical issues 
(Action 14). Furthermore, it aims to help identify areas for possible consensus on ethical principles, 
above all in relation to biomedical applications (e.g. stem cell research, genetic testing); it proposes, 
where appropriate, to set up self-regulatory guidelines for scientists and industry (Action 16).  
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The Commission stresses the role of the bourgeois rather than the citoyen or citoyenne in science 
policy: the consumer should decide what products to buy on the basis of informed choice, and 
thereby influence the technological trajectory (cf. ibid., p. 14). For regulation based on scientific 
assessments, “building public confidence and understanding must be a permanent concern” (ibid.; cf. 
also ibid., p. 16). The scientific community has to take a central position in this dialogue, since it has 
to explain the scientific background to the public (while industry needs to explain the benefits of 
products).  
6 Conclusions   
The Commission has recently turned to the issue of European governance and introduced some 
proposals for changes in the way, the EU can enhance its policy performance. The Commission has 
operationalised some of its ideas for the field of biopolitics; its proposals are dressed in a remarkable 
“participatory talk”. At the same time, it has tried to implement some of the changes is suggests; the 
new food safety regime takes a prominent place.(23) However, the Commission proposals are based, 
firstly, on a narrow concept of participation and, secondly, the shift from a deficit to a trust-based 
model in the field of biopolitics does have its pitfalls. Participation, according to the Commission, 
implies getting all kinds of social actors involved in supranational policy-networks; indeed, this 
basically means top-down consultation of sectoral stakeholders. Some scholars question, if this is 
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with the classical methods, nor with the philosophy which underpins it … Participation can only be 
initiated by the institutions, it is limited to non-decision and mainly directed towards sectoral actors”. 
(Magnette, 2001, p. 5) The various governance papers, particularly the White Paper, do not 
sufficiently – if at all – address the question of the practical realisation of this participatory shift, 
especially with relation to policy issues involving risks. Scharpf (2001, p. 7) even argues that “since 
not a word is lost on the practicalities of Europe-wide participation, one might wonder about the 
seriousness of the invitation itself”. One of the few concrete instruments mentioned for citizen’s 
participation are consensus conferences; however, they are practically very difficult to conduct on 
the supranational level. The advantage of this instrument is that it would allow deliberation between 
experts, citizens and Eurocrats and help to create a sectoral European sphere.  
Furthermore, this shift from deficit to trust is not per se a positive development because it does not 
sufficiently address the relationship between trust and knowledge in risk regulation. First of all, the 
trust model covers up what is, at least partially, the 'deficit model': confidence and understanding are 
mentioned in concert. Yet, understanding can be a major source of distrust. The Commission’s 
policy is not coherent: While it argues for a separation between risk assessment and management 
with regard to the food safety regime, in the policy papers on biotechnology it distinguishes between 
“real” scientific and “false” non-scientific claims. However, who should draw the line? This model 
assumes that trust in the authorities (e.g. regulators, policy-makers, science) is a better source for 
creating legitimacy than knowledge. Yet, trust and knowledge are closely interlinked in many ways. 
How much knowledge and how many control mechanisms does trust require, if we do not want to 
stick to a model of 'blind trust' and fall back on a paternalistic view of the Commission as “a 
benevolent dictator” (Scharpf 2001, p. 7)? What does trust imply in a policy field where diverse 
normative orientations – and even ethical considerations – are as important as opposing interests as 
well as intrinsic limits to knowledge? How much trust is required in the regulators ability to deal 
with the lack of knowledge and the omnipresence of uncertainty? And how much “authority” over 
the dimension of “true science” v. “value-loaded conflicts” does transnational decision-making 
require in order to be effective (Joerges, 2001, p. 15)? Finally, does participation help to build trust 
or could it even diminish the trust in authorities? The Commission does not attend to these issues any 
further.  
15
The relationship between input and output-oriented legitimacy is essential for the debate on 
European governance. The choice is not either input or output, since the deficits are on both sides 
with regard to biopolitics. There are surely options for improving the output side in science-based 
policies without considering participatory means via established (or new) political institutions, for 
example, by transparent and coherent policies within the comitology regime or by regulatory 
agencies. Nevertheless, participatory means may help to improve the legitimacy. However, the 
relation between participation and legitimacy – claiming that more participation leads to better 
policies and thereby to more legitimacy – is, in fact, much more complex than the Commission 
assumes in its various policy papers. Participation guarantees neither legitimacy nor trust. 
Participatory structures do have their own restrictions. Who can participate when and where, under 
which conditions, and in what? Moreover, an emphasis on input-oriented methods can even have 
counterproductive and delegitimising effects given the complexity of the EU and the various sources 
of its legitimacy (cf. Höreth, 1999). Inefficient outcomes of participatory processes can have a 
delegitimising effect on the procedure itself. Participation can, at best, serve as a complement to 
other means of representative democracy, especially in a political system such as the EU where 
participatory procedures are very hard to develop given the multi-level nature of the system and the 
absence of a European public sphere. The lack of this broader contextualisation of the legitimacy 
problem and of its practical difficulties is a major blind spot in the Commission’s vision.  
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labelling of GM food and feed has only started and there is also growing need for a harmonised 
policy in some areas of biomedicine, which is not restricted to the contested area of embryo research. 
In many EU member states, biopolitics has become a field for political experiments with alternative 
ways to create legitimacy which require deliberation between experts, citizens and policy-makers in 
order to solve the dilemma of science v. society. It could also serve as an experimental field at the 
supranational level. Therefore, the significance of the new food safety regime goes way beyond 
sectoral innovations in institutional design and legitimacy-building, but it could be a test case for the 
opportunities of participatory European governance and in this way may teach us some lessons for 
the broader issue of EU legitimacy.  
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Endnotes  
(*) This paper has benefited a lot from the comments and suggestions of the two anonymous EIoP 
reviewers, of the participants of the workshop on Biomedicine at the ECPR Joint Session of 
Workshops in Turin, March 2002, and of Thomas Saretzki. I am furthermore indebted to Joyce 
Mushaben and Christina White for their language support.  
(1) The term “biopolitics” is not used in the Foucaultian sense, but in analogy to the political science 
terms of politics, policy and polity as suggested by Robert Blank and Samuel Hines (2001, 6ff.; 
99ff.). In this sense, biopolitics, for example, refers to the political processes and conflicts related to 
the political management of biotechnology. 
(2) In 2002, there was intense debate among the EU institutions about the question, if this kind of 
research should be funded with EU money. The compromise finally achieved states that no such 
research shall be funded until the end of 2003. Until that time, the Council shall decide on bioethical 
guidelines.  
(3) Tension and competition between the executive and the legislative branch have been a central 
motive for the founding parliamentary TA institutions in general.  
(4) STOA is important for the co-ordination of parliamentary TA institutions in Europe via the 
European Parliamentary TA Network (EPTA) founded in 1990 and financed by STOA. 
(5) The Biomed I programme (1990-1994) earmarked 4.67 Mio. ECU for ELSA studies. ELSA 
became a horizontal activity in the fourth framework programme (1994-1998), i.e. it was extended to 
all research in the life sciences. Subsequently, ELSA studies were also conducted under the 
BIOTECH and the FAIR (Fisheries and Agriculture Research) programme, and an ELSA 
concertation group was set up. The fifth framework programme introduced bioethical guidelines. 
Projects funded with EU money have to follow the Helsinki Declaration on medical research 
involving human subjects (1964), the UN “Universal Declaration on the Human Genome and Human 
Rights” (1998), and the Council of Europe “Convention on Human Rights and Biomedicine” (1997). 
Even if the EU as such could not ratify the Bioethics Convention, it nevertheless adopted it as a 
major ethical framework for its funding policy. For international bioethical regimes cf. Braun 2000. 
(6) EGE’s main tasks are: “To help break down barriers between disciplines in fields which require a 
multi-disciplinary approach, not only scientific and legal, but also philosophical, sociological and 
economic; to provide European decision-makers (i.e. also the Parliament and the Council; G.A.) with 
clear and up-to-date basic information, enabling them to be properly informed in carrying out their 
duties; and to promote dialogue that stimulates mutual tolerance so that all viewpoints can be 
expressed before the Community authorities decide on appropriate regulations.” (EGE, 2001) 
(7) Article 3 of the Charter states that eugenic practices, the use of the human body (or parts of it) for 
profit-making and reproductive cloning are prohibited. In addition, some EU member states and 
institutions want to make this ban on reproductive cloning global. In 2001, France and Germany 
proposed a UN convention against such cloning. The European Commission and the European 
Parliament have suggested to the other member states to support the Franco-German proposal in the 
UN. 
(8) The European Parliament and Council Directive 98/44/EC on the protection of biotechnological 
inventions (patenting directive) is, of course, a most important regulation for research and product 
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judgements on the patentability of human genes and parts of the human body. Since this directive is 
of no direct relevance for my hypothesis, I will not attend to it any further in this paper. 
(9) For a detailed discussion of this case and its effects cf. Toeller/Hofmann, 2000; Hofmann/Töller, 
1998; Bradley, 1998. 
(10) The ban on market authorisation has also influenced the applications for the approval of field 
experiments, the second aspect regulated in Directive 90/220/EEC respectively 2001/18/EC. The 
number of approvals decreased enormously in all member states since 1999. 
(11) Further safeguards concern risk assessment, monitoring and traceability of GMOs, time limited 
authorisation, and a ban of markers for antibiotic resistance from 2005 onwards. 
(12) The crisis revealed the Commission’s selective use of scientific expertise, its mismanagement, 
its strong focus on the market (instead of consumer protection), and implementation deficiencies; it 
led to growing distrust of the public towards regulators in the members states as well as on the 
supranational level (cf. Joerges, 2001, 6ff.; Neyer 2000; Vogel 2001, 12ff.). Furthermore, it gave the 
European Parliament a first opportunity to exercise new powers via establishing an inquiry 
committee (Shackleton, 1998). 
(13) The conflict focuses, amongst other things, on a threshold for labelling. In its position adopted 
on July 2, 2002, Parliament opts for a lowered maximum threshold for labelling (0.5% instead of 
1%). With regard to the issue of participation, the new proposal for GM food and feed suggests a 
more inclusive consultation process by making the application for market release and the risk 
assessment available to the public for comment (cf. Commission, 2002b, 22; Commission, 2002c). 
(14) Many member states are now in “a mood for dialogue”, as Alan Irwin (2001) calls it. For 
example, most member states have earmarked funding for research into ethical issues and 
(participatory) TA; moreover, they have integrated bioethics into policy-making and policy advice, 
e.g., by establishing permanent national ethics committees. The relationship between science and 
democracy in the biosciences has been subject of several government reports in Britain; participatory 
instruments such as a public consultation and a citizen foresight project have been put to the test. 
Many member states have acquired experiences with consensus conferences, citizens’ juries and 
other methods of so-called participatory TA, particularly in relation to biomedicine and 
biotechnology (cf. Klüver et al., 2000; Joly/Assouline, 2001). In Germany, the year 2001 was 
declared “the year of the life sciences”; exhibitions, series of discussions, and the first German 
national consensus conference on genetic testing supported by the federal ministry of research 
BMBF were sold as “science in dialogue”. The Netherlands has seen a broad public debate on 
biotechnology invoked by the parliament. So there have been many activities in the member states 
promoting a dialogue between experts, citizens and policy-makers. 
(15) Some developing countries have recently either banned the import of GM crops in the 
framework of international food aid or allow it under strict conditions only. 
(16) The EU-US Consultative Forum, a body established in the early 1990s to discuss controversial 
issues over biotechnology, states in its report in 2000: “transparency in decision taking, inclusive and 
meaningful participation (act) as the foundations of confidence in public institutions” (quoted in 
Gaskell/Bauer, 2001, 116). 
(17) This view is supported by the Council. At the Nice summit in 2000, the heads of government 
have furthermore decided in their resolution on the precautionary principle that it shall also include 
greater civic participation to embrace all possible views in risk assessment (Vogel, 2001, 16).
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al. (1999) commissioned by the Director General for Consumer Protection (DG XXIV) and 
eventually found its way into the White Paper on Governance and the EFSA structure. I am grateful 
for this hint to one of the EioP commentators.  
(19) For an extensive critique of the White Paper cf. the contributions in Grote/Gbikpi, 2002; Joerges 
et al., 2001; also Wincott, 2001. 
(20) Due to the strong economic incentive, the EU favours producer interests over other societal 
interests. At the same time, the institutions and most of all the Commission acknowledge this bias 
and try to balance opposing interest by promoting the organisation of some so-called 'weak' and 
'diffuse' interests, e.g. in the environmental sector (cf. Mazey/Richardson, 2001; Pollack, 1997). 
(21) A consensus conference is a form of TA conducted by lay-people. Proponents cherish this 
method as a form of participatory democracy and as an alternative model for shaping the relationship 
between citizens and experts. The premise or participatory TA is that “many sciences and 
technologies have … far-reaching and direct repercussions for individuals and society at large; hence 
there is a need to bring ethical, environmental and social implications into play. … the evaluation of 
scientifically and socially complex issues … by exclusive expert bodies has come in for increasing 
public criticism for disregarding viewpoints and interests other than their own, and lacking public 
accountability” (Joss, 1998, 2f.). Many EU member states have experience with this instrument; a 
thematic focus has been on biotechnology and biomedicine. The structure of the political system and 
the underlying socio-political culture are decisive for the success or failure of the procedure (cf. 
Klüver et al., 2000). However, consensus conferences at the European level – whether pan-European 
or simultaneously in all (or some) member states – bring along severe practical difficulties, firstly, of 
recruiting lay-people for the citizen’s panel, secondly, for deliberations of lay-people given the 
multiplicity of languages, and, thirdly, for the proper institutional environment on the supranational 
level. 
(22) They point out that, for example, the problem of values in scientific risk assessment is taken up 
in the paper on democratising expertise. This results in tensions and contradictions between the 
various Commission documents (Levidow and Marris, 2001, 351f.). 
(23) Further examples are the enhanced role of expert committees in the Commission. When the 
Charter of Fundamental Rights was under debate in 2000, President Prodi asked the European Group 
on Ethics for a report on how the Charter would affect citizens’ rights in relation to new technologies 
(EGE, 2000). In addition, a Life Sciences High Level Group was formed in April 2000. Concurrently 
with the consultation process for a strategy for biotechnology, the Commission organised a first 
“stakeholder conference”, held in September 2001. One medium enjoying great popularity also in 
the science/society debate is the Internet. The Commission has established an Internet forum on 
“Biosociety”, which is meant to serve as a “playground for open and pluralistic debates”. Finally, the 
Commission itself is funding research on the relationship between citizens and governance 
particularly with regard to a knowledge-based economy via its framework programmes for RTD. 
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